Taking a lower total weekly dose, say 2mg instead of the target 4mg, while splitting it into smaller frequent injections
Both subgroup analyses demonstrated non-significant differences in WL between the GLP-1RAs and placebo groups with (SMD = 0.44, 95% CI -0.37 to 1.26) and (SMD = 0.74, 95% CI -0.32 to 1.79), respectively (Fig
Your clinician may: Screen with a tool like the PHQ-9 Adjust the Tirzepatide dose Suggest a temporary pause Add psychiatric support Discuss all your medications and supplements so your team can check for interactions or overlapping side effects
Gastrointestinal side effect timing Beyond nausea, GLP-1 agonists can cause constipation, diarrhea, bloating, and acid reflux
Three properties drive it: 1
What we know with confidence Tesamorelin reduces visceral fat in HIV-positive patients with lipodystrophy